Financial Data and Key Metrics Changes - The company processed approximately 924,000 tests in Q4 2025, achieving a record growth of 56% in MRD clinical unit tests compared to Q4 2024 [6][10] - Revenue for the quarter reached around $666 million, representing a 40% increase year-over-year [6][7] - Gross margin improved to 66.9% in Q4, exceeding expectations and reflecting strong operational performance [6][11] - Cash flow generated in 2025 was over $107 million, with expectations for continued strong cash flow in 2026 [7][30] Business Line Data and Key Metrics Changes - The MRD product portfolio expanded significantly with the launch of the genome version of Signatera and the Latitude MRD test, contributing to strong growth in oncology [8][9] - The average selling price (ASP) for Signatera increased to approximately $1,225 in Q4, with cash collections accelerating [11][30] - The women's health segment saw robust performance, particularly with the Fetal Focus test, which achieved high sensitivity and specificity [15][16] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4, indicating strong adoption of MRD testing in clinical practice [10] - The company is seeing increased engagement from commercial payers, enhancing reimbursement opportunities for its tests [12][30] Company Strategy and Development Direction - The company plans to generate between $2.62 billion and $2.7 billion in revenues for 2026, with a focus on maintaining gross margins between 63% and 65% while investing in R&D [7][31] - Strategic investments in clinical trials and product launches are expected to drive future growth, particularly in oncology and women's health [8][36] - The company is pursuing broader Medicare reimbursement for Signatera, which could significantly enhance revenue potential [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong performance in Q4 and a solid start to 2026 [6][7] - The company is focused on maintaining operational improvements and expects to continue narrowing operating losses while investing in growth [30][31] - Management highlighted the importance of generating clinical evidence to support product adoption and reimbursement [46][61] Other Important Information - The company completed the acquisition of Foresight Diagnostics, integrating phased variant technology to enhance MRD test sensitivity [27][28] - The Latitude MRD assay has shown promising clinical validation, with significant prognostic capabilities for colorectal cancer [24][25] Q&A Session Summary Question: Update on Signatera ASPs and Medicare changes - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement expected to drive ASP growth [38][39] Question: Signatera mix by indication and potential impact on ASPs - The majority of Signatera volume comes from CRC, but management anticipates that breast and lung cancer indications will gain traction, potentially impacting ASPs positively [41][42] Question: Growth expectations for Signatera and data catalysts - Management suggested using trailing four-quarter averages for modeling growth, with expectations for continued strong performance across various tumor types [45][50] Question: Marketing approach for Fetal Focus and market share - Management noted significant physician interest in Fetal Focus, with flexible ordering options contributing to market share gains [52][54] Question: Contribution from lymphoma and multiple myeloma volumes - Management acknowledged limited current contributions from these areas but sees potential for growth driven by the Foresight team and their data [74][75] Question: Approval and launch plans for Signatera in Japan - Management confirmed a strong sales team and distribution partnership in Japan, anticipating a positive impact on revenue once approval is secured [76][79]

Financial Data and Key Metrics Changes - The company generated approximately $666 million in revenue for Q4 2025, representing a 40% increase compared to Q4 2024 [6][30] - Gross margin for the quarter was 66.9%, exceeding expectations and reflecting a significant improvement [6][11] - Cash flow for the year reached over $107 million, indicating strong financial health despite increased growth investments [7][30] Business Line Data and Key Metrics Changes - The company processed about 924,000 tests in Q4 2025, with MRD clinical unit growth reaching 225,000 tests, a 56% increase year-over-year [6][10] - Average selling prices (ASPs) for Signatera increased to approximately $1,225 in Q4 2025, contributing to revenue growth [11][30] - The Women's Health segment saw significant growth, particularly with the launch of the Fetal Focus test, which is expected to drive further market share gains [15][54] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4 2025, indicating strong adoption of MRD testing in clinical practice [10] - The company anticipates continued growth in Women's Health volumes and ASPs, with a strong start to 2026 [33][64] - The Organ Health products are expected to maintain a growth trajectory, driven by the increasing relevance of cell-free DNA in patient care [64] Company Strategy and Development Direction - The company plans to generate between $2.62 billion and $2.7 billion in revenues for 2026, with a focus on maintaining gross margins between 63% and 65% [7][31] - Investments will continue in R&D and clinical trials, particularly in MRD and early cancer detection technologies [36] - The company is pursuing broader Medicare reimbursement for Signatera, which could enhance ASPs and revenue potential [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, citing strong performance in Q4 2025 and a solid start to 2026 [6][7] - The management highlighted the importance of clinical data generation and its role in expanding market share across various cancer types [20][61] - There is a clear path to profitability, with a focus on balancing growth investments and operational efficiency [30][36] Other Important Information - The company has submitted its Latitude tissue-free MRD assay to MolDX, which is expected to enhance its product offerings in colorectal cancer [24][26] - The acquisition of Foresight Diagnostics is anticipated to strengthen the company's capabilities in MRD testing [27][30] Q&A Session Summary Question: Can you discuss the net ASP impact from changes in Medicare rates? - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement expected to drive ASP growth [38] Question: What is the current mix of Signatera by indication? - The majority of Signatera volume is currently from colorectal cancer, but other tumor types are beginning to accelerate, with a significant focus on expanding coverage for additional indications [41][68] Question: How does the company view the potential for growth in heme MRD volumes? - Management acknowledged that while the current contribution from heme MRD volumes is limited, there is significant upside potential as the company leverages its recent acquisition and data generation capabilities [74] Question: What are the expectations for the Women's Health market in 2026? - The company expects to see mid-single-digit growth in Women's Health volumes, with potential for revenue growth driven by pricing gains [64]

Financial Data and Key Metrics Changes - The company processed approximately 924,000 tests in Q4 2025, with MRD clinical unit growth reaching 225,000 tests, a 56% increase compared to Q4 2024 [5][10] - Revenue for the quarter was around $666 million, representing a 40% growth year-over-year [5][6] - Gross margin for Q4 was reported at 66.9%, exceeding expectations and reflecting strong operational performance [5][11] - Cash flow generated in 2025 was over $107 million, with expectations for continued strong cash flow in 2026 [6][29] Business Line Data and Key Metrics Changes - The MRD product portfolio was significantly expanded with the launch of the genome version of Signatera and the Latitude MRD test [9][25] - The Fetal Focus single gene NIPT test was launched, addressing unmet clinical needs and showing robust performance metrics [12][14] - The organ health portfolio, particularly the Prospera donor DNA monitoring, continues to evolve, with significant investments aimed at improving clinical utility [16][18] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4, indicating strong adoption of MRD testing in clinical practice [10] - The company anticipates continued growth in women's health volumes and ASPs, with a strong start in Q1 2026 [32][62] - The organ health products are expected to maintain a growth trend, driven by the increasing relevance of cell-free DNA in patient care [62] Company Strategy and Development Direction - The company plans to invest in R&D while holding SG&A stable, focusing on targeted investments to drive future growth [6][36] - There is a strong emphasis on expanding reimbursement coverage for Signatera, with ongoing efforts to secure broader Medicare reimbursement [12][30] - The integration of AI-enabled workflows is expected to enhance operational efficiency and reimbursement processes [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operational and financial outlook for 2026, expecting revenue between $2.62 billion and $2.7 billion [6][30] - The company is focused on maintaining a path to profitability while continuing to invest in growth opportunities [29][36] - Management highlighted the importance of generating clinical evidence to support product adoption and market expansion [19][46] Other Important Information - The company has submitted its Latitude MRD assay to MolDX for colorectal cancer, which is expected to enhance MRD assessment capabilities [24][25] - The phased variant technology integrated into the Signatera platform is anticipated to improve detection sensitivity significantly [25][26] Q&A Session Summary Question: Can you discuss the net ASP impact from changes in Medicare rates? - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement for covered services expected to drive ASP growth [38] Question: What is the current mix of Signatera by indication? - The majority of Signatera volume is currently from CRC, but management expects other tumor types like breast and lung to gain traction, potentially normalizing the mix over time [66] Question: What are the expectations for women's health market share in 2025? - The company reported a record year in women's health and anticipates further growth with the introduction of the Fetal Focus test, which is expected to attract new customers [82]

Natera, Inc. Q4'2025 Earnings Presentation February 26, 2026 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partnerships and potential acq ...

Core Insights - Natera, Inc. has announced the publication of a new prospective clinical trial in Transplantation Direct, focusing on donor-derived cell-free DNA (dd-cfDNA) surveillance [1] - The study was conducted by The Ohio State University Wexner Medical Center (OSU-WMC) to evaluate whether Prospera-guided monitoring can reduce the number of invasive biopsies for patients [1] Company Overview - Natera, Inc. is recognized as a global leader in cell-free DNA and precision medicine [1] - The company is actively involved in advancing non-invasive monitoring techniques in the field of transplantation [1] Industry Context - The trial aims to enhance patient care by potentially minimizing the need for invasive procedures, which is a significant concern in transplantation medicine [1] - The use of dd-cfDNA surveillance represents a growing trend in precision medicine, emphasizing the importance of non-invasive diagnostic methods [1]

Core Insights - Natera's mission is to transform disease management globally through proprietary technology that detects minute quantities of DNA, combining molecular and bioinformatics techniques [2] - The company launched its first product, Panorama, in 2013, a cell-free fetal DNA test for chromosomal abnormalities, and has since become the market leader with over 50% market share [3] - Natera has expanded its technology applications to organ health with Prospera, which non-invasively identifies organ transplant rejection using donor-derived cell-free DNA, and to oncology with Signatera, which monitors minimal residual disease and recurrence through circulating tumor DNA [3]

Summary of Natera's Conference Call Company Overview - **Company**: Natera - **Industry**: Life Sciences, Diagnostics, Oncology, Women's Health - **Core Mission**: Transforming disease management globally through proprietary technology that detects small quantities of DNA [2][3] Key Products and Market Position - **Panorama**: A cell-free fetal DNA test for chromosomal abnormalities, leading with over 50% market share [2] - **Prospera**: A test for organ transplant rejection using donor-derived cell-free DNA [2] - **Signatera**: A circulating tumor DNA test for minimal residual disease (MRD) monitoring, achieving record growth with 22,000 clinical MRD tests in Q4 [3][4] Financial Performance - **Q4 2025 Revenue**: $660 million, up 39% year-over-year, driven by strong average selling prices (ASPs) and volume growth [4] - **Free Cash Flow**: Exceeded $100 million for the year [5] - **Unit Sales**: 924,000 units in Q4, with significant growth in oncology and women's health [3][4] Innovations and Future Growth Drivers - **Fetal Focus**: A new 21-gene single-gene NIPT test aimed at severe genetic disorders, filling a gap in clinical care [5][6] - **Signatera Enhancements**: Incorporation of phased variants technology for improved sensitivity, targeting a limit of detection (LOD) down to one part per 10 million [10][11] - **AI Integration**: Development of an augmented MRD score using AI and a foundation model to enhance precision in risk assessment [12][13] Clinical Trials and Partnerships - **Clinical Trials**: Significant investments in clinical trials, particularly in breast cancer, with over $100 million allocated for evidence generation [16][17] - **STELLAR Trial**: A pivotal phase three trial in colorectal cancer, leveraging Signatera for patient enrollment [18][35] - **Partnerships**: Collaborations with NVIDIA for AI initiatives and Ultima Genomics for new product launches [22] Market Dynamics and Competitive Landscape - **Market Share**: Natera holds over 50% market share in women's health and is focused on maintaining and expanding its position through innovation and clinical evidence [25][39] - **Lymphoma Market**: Interest in expanding into lymphoma and hematologic cancers, leveraging Foresight Diagnostics' technology [27][28] Regulatory and Reimbursement Strategies - **Medicare Coverage**: Ongoing efforts to expand Multi-X coverage, with 30% of tests currently not covered under Medicare [21] - **Reimbursement Process**: Coordination with MolDX for new assay coverage, emphasizing the importance of generating data [32] Future Outlook - **2026 Goals**: Plans to complete enrollment for the FIND study in early cancer detection and launch new products incorporating advanced technologies [21][22] - **Operating Margins**: Expectation of growing into profitability as revenue matures, with a focus on maintaining operational efficiency [46][48] Conclusion Natera is positioned for significant growth through innovative product offerings, strategic partnerships, and a strong focus on clinical evidence generation. The company aims to leverage its market leadership in diagnostics to expand into new therapeutic areas while enhancing its existing product lines.

Summary of Natera (NTRA) FY Conference Call - August 12, 2025 Company Overview - Natera is a leader in cell-free DNA-based testing focused on women's health, oncology, and organ health [1] Key Points Performance Metrics - In Q2, Natera achieved a record of approximately 189,000 total units, with a sequential growth of about 20,000 units from Q1 [5][6] - Clinical units specifically for Signatera reached about 180,000, marking a significant increase compared to the average growth of 13,000 to 14,000 units per quarter in the previous year [6][7] - New patient starts contributed significantly to growth, with around 6,000 new starts in Q2, compared to an expected 2,500 [7][8] Market Dynamics - The company noted a competitive landscape with several new MRD tests entering the market, but expressed confidence in Signatera's unique value proposition [15][16] - Natera's strategy includes welcoming competition as it validates the market and enhances patient care [16][17] Clinical Data and Product Development - Recent clinical trial data, particularly in colorectal cancer, has driven interest and adoption of Signatera [10][12] - Natera is expanding its product offerings, including a genome backbone version of Signatera and a tumor-naive MRD assay [19][20] - The company anticipates significant revenue opportunities from new indications reimbursed by Medicare, estimating an incremental revenue potential of $250 million to $300 million [28][29] Financial Outlook - Natera raised its revenue guidance significantly while maintaining operating expense guidance, indicating a focus on sustainable cash flow generation [41][42] - The company aims for long-term gross margins of around 70%, having improved from 39% to 63% over the past two years [46][48] Future Opportunities - Natera is preparing for the launch of an FDA-approved screening test for colon cancer by 2028, which could align with USPSTF guidelines [34][35] - The company is optimistic about upcoming clinical trial data that could further enhance its market position and treatment paradigms in oncology [52][53] Strategic Focus - Natera emphasizes a patient-centric approach, focusing on addressing unmet needs and expanding its product portfolio based on customer feedback [50][51] - The company is committed to maintaining a balance between investment in growth and generating returns for investors [49][50] Additional Insights - The company is leveraging its existing NIPT database to inform its early cancer detection (ECD) assays, which could enhance its competitive edge [39] - Natera's operational strategy includes a focus on long-term clinical trial outcomes to support guideline adoption for its tests [31][32] This summary encapsulates the critical insights and data points from the Natera conference call, highlighting the company's performance, market dynamics, product development, financial outlook, and strategic focus.

Financial Data and Key Metrics Changes - The company generated $547 million in revenue, representing a 32% growth over Q2 of the previous year, and a 34% growth when excluding revenue true-ups [6][8] - Gross margin increased to 63.4% compared to approximately 59% in the same quarter last year, with consistent margins sequentially versus Q1 [7][14] - The revenue guidance for the year has been raised by $80 million, now expecting revenues in the range of $2.1 billion to $2.2 billion [8][56] Business Line Data and Key Metrics Changes - The company processed 189,000 oncology tests in the quarter, marking a growth of nearly 20,000 units compared to Q1, setting a new milestone [7][11] - Significant growth was noted in the Signatera product line, with new patient starts doubling the previous quarterly record [7][12] - Women's health products had their second-best volume quarter ever, despite seasonal trends [10] Market Data and Key Metrics Changes - The company is seeking Medicare reimbursement for additional tumor types, which could yield approximately $250 million to $300 million in annual revenue [13] - The company reported a record low in Days Sales Outstanding (DSOs) at 57 days, indicating improved cash collection efficiency [15] Company Strategy and Development Direction - The company is focused on expanding its product offerings, including the launch of Fetal Focus, a new NIPT for inherited conditions [9][26] - Investments are being made in artificial intelligence to enhance diagnostic capabilities and operational efficiency [25][46] - The company aims to maintain operating expenses while increasing revenue, indicating a strategy of scaling without proportional increases in costs [20][58] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong data and increased adoption of products [6][8] - The company is positioned to leverage its existing infrastructure to expand its market presence and improve patient outcomes [75] - Management highlighted the importance of upcoming clinical trial readouts, which could significantly impact practice guidelines [66][68] Other Important Information - The company exited its legacy paternity business, which had previously contributed to volume numbers [10] - The PEDAL study published in a high-impact journal demonstrates the potential of donor-derived cfDNA in predicting kidney transplant outcomes [30][31] Q&A Session Summary Question: What drove the record Signatera volumes? - Management noted strong data presentations at ASCO and significant growth in new patient starts, indicating a broad adoption of the product across various tumor types [61][63] Question: What are the key upcoming clinical trials? - Management highlighted the INVIGOR-11 trial and several colorectal trials that could influence guidelines and practice [66][68] Question: How is the company addressing the competitive landscape in early cancer detection? - Management emphasized their in-house R&D capabilities and the alignment of their PROCEED trial with FDA protocols, aiming for a strong performance readout [79][80]

Financial Data and Key Metrics Changes - The company generated $547 million in revenue, representing a 32% growth year-over-year, and a 34% growth when excluding revenue true-ups [5][6] - Gross margin increased to 63.4% compared to approximately 59% in the same quarter last year [6][15] - The company raised its revenue guidance by $80 million, now expecting revenues in the range of $2.1 billion to $2.2 billion [7][58] Business Line Data and Key Metrics Changes - The company processed 189,000 oncology tests in the quarter, marking a sequential growth of 20,000 units, which is a new milestone [6][11] - Signatera saw record growth in both sequential growth and new patient starts, with new patient starts being double the previous quarterly record [6][12] - Women's health products had the second-best volume quarter ever, following a strong Q1 [10] Market Data and Key Metrics Changes - The company is seeking Medicare reimbursement for additional tumor types, which could represent an annual revenue opportunity of $250 million to $300 million [13] - The company reported a significant increase in cash collections, with days sales outstanding (DSOs) down to 57 days, a record low [16] Company Strategy and Development Direction - The company is focused on launching new products, including Fetal Focus, a new NIPT for inherited conditions, and expanding its oncology data pipeline [8][30] - Investments are being made in artificial intelligence to develop new diagnostic biomarkers and improve operational efficiencies [19][47] - The company aims to maintain operating expenses while increasing revenue, indicating a strategy of scaling without proportional increases in costs [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong data and new patient starts as key drivers [6][12] - The company is committed to maintaining cash flow positivity while investing in growth opportunities [60] - Management highlighted the importance of upcoming clinical trial readouts and their potential impact on market positioning [70][81] Other Important Information - The company exited its legacy paternity business, which had historically contributed to volume numbers [10] - The PEDAL study published in a high-impact journal demonstrated the utility of donor-derived cfDNA in predicting long-term outcomes after kidney transplant rejection [30][31] Q&A Session Summary Question: What drove the record Signatera volumes? - Management noted strong data presentations at ASCO and significant growth in colorectal and breast cancer monitoring as key drivers, along with a record increase in new patient starts [62][63] Question: What are the important upcoming clinical trials? - Management highlighted the INVIGOR-11 trial and several colorectal trials that could influence guidelines and practice [66][70] Question: How is the company addressing the competitive landscape in early cancer detection? - Management emphasized their in-house R&D capabilities and the alignment of their PROCEED trial with FDA protocols as a strategic advantage [80][81]